Recent Updates
Recently added Catalysts
INO Positive Sentiment Score: 70/100

INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference

Key Takeaway: INOVIO (NASDAQ: INO) has announced that its President and CEO, Dr. Jacqueline Shea, will present at the 2023 RBC Capital Markets Global Healthcare Conference on May 17, 2023. The format includes a fireside chat, and members of INOVIO's management will also conduct one-on-one meetings with registered investors. The company focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, providing a platform for potential future developments in these areas.

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO will present at a reputable healthcare conference, showcasing their innovations.
  • Dr. Jacqueline Shea, as CEO, demonstrates leadership in engaging with investors.
  • The presentation offers potential visibility and opportunities for investor engagement.

Full Press Release Details

PLYMOUTH MEETING, Pa., May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the 2023 RBC Capital Markets Global Healthcare Conference.
2023 RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 17, 2023
Format: Fireside Chat
During the conference, Dr. Shea and members of INOVIO's management team will conduct one-on-one meetings with registered investors.
A webcast of the presentation will be available on the INOVIO Investor Relations Events page at https://ir.inovio.com/events-and-presentations/default.aspx. A replay of the webcast will be available for 90 days after the date of the presentation.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Media: Jennie Willson (267) 429-8567 [email protected]
Investors: Thomas Hong (267) 440-4298 [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

What is INOVIO focused on developing?

INOVIO specializes in DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases.

When will Dr. Jacqueline Shea present at the conference?

Dr. Jacqueline Shea will present at the RBC Capital Markets Global Healthcare Conference on May 17, 2023.

How can I access the presentation webcast?

The webcast will be available on INOVIO's Investor Relations Events page.

Is there a replay available for the presentation?

Yes, a replay of the presentation will be available for 90 days post-event.

What device does INOVIO use for its DNA medicines?

INOVIO employs an investigational device called CELLECTRA® to deliver its DNA medicines.

Last updated: May 5, 2023